De-intensification of cancer treatment improves quality of life and maintains outcomes

In new commentary published in Nature Cancer, researchers from the University of Melbourne Centre for Cancer Research and Peter MacCallum Cancer Centre have outlined a case for de-intensifying cancer treatment in certain patients to improve quality of life and reduce healthcare costs, while maintaining cancer outcomes.

The de-intensification of cancer care aims to avoid overtreatment by reducing treatment dose, duration or frequency, or omitting certain treatment phases altogether, while still preserving positive outcomes. It may involve using biomarkers or decision-support tools to guide selection of the most appropriate patients and treatments.

According to lead author Dr Jennifer Soon, from the Cancer Health Services Research group, de-intensification represents an under-utilised but potentially high-impact strategy, especially for a cancer like melanoma where treatments are often associated with significant toxicities and costs.

"Improvements in cancer diagnosis and care have extended many lives, but aggressive treatments can take a toll on patient quality of life and stretch limited healthcare resources," said Dr Soon.

"When appropriate clinical benchmarks are met, de-intensifying treatment can spare patients from unnecessary side effects, travel burdens, and out-of-pocket costs while still ensuring positive cancer outcomes."

A secondary benefit of de-intensification is improving environmental sustainability, through reducing healthcare waste, resource requirements like staffing and consumables, and patient travel emissions—though these societal gains must be weighed against individual patient needs supported by robust data in the absence of high-quality evidence.

While highly promising, de-intensification faces hurdles including patient fears about heightened recurrence risk. Physician concerns about undertreatment and a lack of robust clinical trial data to guide new protocols can also be a barrier.

To overcome these challenges, the researchers call for expanded research funding, improved trial design, and strong medical leadership to build the evidence base and support de-intensification's implementation into routine clinical care.

"More treatment doesn't necessarily mean better outcomes, especially as survivorship increases and quality-of-life factors become paramount," said Dr Soon.

"De-intensification is an opportunity to deliver personalised cancer care in a more holistic and sustainable way for patients and healthcare systems alike."